Menopausal Flushing Clinical Trial
Official title:
Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
Placebo-controlled, double-blinded, cross-over clinical trial of a new investigational product
Double-blinded, placebo-controlled, 2-way crossover study in 30 menopausal women with untreated hot flushes treated with a neurokinin 3 receptor (NK3R) antagonist Aims: To investigate whether an NK3R antagonist can reduce menopausal flushing Treatment: 4 weeks administration of active drug and placebo in random order ;